Haematopoietic Stem Cell Transplantation

Open Access

Abstract

Around 50,000 hematopatio stem cell transplants are done each year for the treatment of lymphoma, leukemia, immune deficiency diseases, and immunodefetocs, and hematopathies, and myelogenous and myelomen syndromes. Prior to transplantation, patients undergo myeloablative chemoradiation, after which they receive extensive “rescue” cell treatment a method of allogeneic HSCT is done by reinfusing the patient's own bloodderived stem cells, which are collected before transfusion. The stem cells used in allogeneic HSCT are human leukocyte antigens (HLA) balanced Allogeneic survival after transplantation depends on donor/patient pairing, the graft/recipient response, and the frequency of a donor leukemia impact. This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications.